SI-BONE Inc

SI-BONE, Inc. engages in the provision of implantable devices used in the surgical treatment of the sacropelvic anatomy. It offers a proprietary minimally invasive surgical implant system, called iFuse, used to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that often causes severe lower back pain. The company was founded by Mark A. Reiley and Jeffrey W. Dunn on March 2008 and is headquartered in Santa Clara, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

SI-BONE reports record Q4 revenue, eyes global growth opportunities

SI-BONE's Q4 2022 performance reflects robust revenue growth and operational improvements, driven by increased surgeon engagement and product adoption.
The company's financial stability, strong cash position, and strategic focus on growth opportunities position it well for future success and market expansion.
While facing challenges such as undisclosed study enrollment and international growth pacing, SI-BONE's focus on operational efficiency and market opportunities presents a positive outlook for sustained growth and profitability.

SI-BONE Inc reports robust Q1 revenue growth and raises 2023 guidance

SI-BONE Inc had a strong Q1 performance with robust revenue growth and surgeon adoption. While facing some challenges with expense increases, the company is optimistic about future growth opportunities and aims for improved financial performance throughout 2023.

SI-BONE Inc reports robust Q2 growth and optimistic outlook

SI-BONE Inc's Q2 2023 showcased strong revenue growth, improved operational efficiency, and enhanced cash position.
Company's product portfolio, FDA clearances, and revenue guidance revisions underscore its growth potential and market competitiveness.
Challenges include managing increased operating expenses, evolving marketing strategies, and maintaining growth momentum.
Opportunities lie in expanding surgeon base, leveraging training programs, conducting market studies, and aiming for a strong second half performance.

SI-BONE reports record revenue in Q3 2023, eyes market expansion

SI-BONE's Q3 2023 earnings call showcased robust financial performance, strong market positioning, and growth prospects. With record revenue, increased guidance, and a focus on innovation and market expansion, SI-BONE is well-positioned for continued success in the medical device industry.

SI-BONE reports record revenue growth and strategic product launches

SI-BONE Inc delivered strong financial performance in Q4 2023, with record revenue, improved EBITDA, and a solid cash position for future growth initiatives.
The company's strategic strengths lie in its U.S. market dominance, innovative product launches, and positive revenue guidance for 2024.
Challenges include expanding international revenue, pricing competitiveness, and effective training for new products, while opportunities exist in market expansion and product innovation.
Overall, SI-BONE's performance highlights its resilience, growth potential, and strategic focus on driving innovation and market expansion in the medical device sector.

SI-BONE Inc reports robust Q1 revenue growth and strategic focus

SI-BONE Inc's Q1 performance reflects strong revenue growth and operational achievements, underpinned by strategic priorities and market differentiation. While facing challenges in expense management and profitability, the company is well-positioned to capitalize on opportunities through innovation and market disruption.

SI-BONE Inc reports strong Q2 earnings, eyes growth opportunities

SI-BONE Inc delivered robust financial performance in Q2 2024, driven by revenue growth, increased active physicians, and improved EBITDA.
The company's strengths lie in customer loyalty, innovation, leadership enhancements, and a clear path to financial sustainability.
Challenges include operational scalability, sustaining revenue growth, balancing innovation with cost control, and effective Board integration.
Opportunities for SI-BONE include accelerating revenue growth, expanding into new market segments, diversifying product offerings, and leveraging strategic Board additions.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SI-BONE, Inc. is a medical device company, which engages in the provision of a proprietary minimally invasive surgical implant system to fuse the sacroiliac joint for treatment of musculoskeletal disorders of the sacropelvic anatomy. It offers a proprietary minimally invasive surgical implant system, called iFuse, used to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that often causes severe lower back pain. The company was founded by Mark A. Reiley and Jeffrey W. Dunn on March 18, 2008 and is headquartered in Santa Clara, CA.

Si-Bone (SIBN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Si-Bone (SIBN) Q3 Earnings Expected to Decline

SANTA CLARA, Calif., Oct. 18, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the third quarter of 2021 after market close on Monday, November 8, 2021. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

SI-BONE To Report Third Quarter 2021 Financial Results on November 8, 2021

The transition to an exclusive triangular implant policy by UnitedHealthcare, the nation's largest health insurer, is supported by over 100+ peer-reviewed publications, and comes as SI-BONE surpasses 60,000 iFuse procedures performed by more than 2,500 surgeons worldwide The transition to an exclusive triangular implant policy by UnitedHealthcare, the nation's largest health insurer, is supported by over 100+ peer-reviewed publications, and comes as SI-BONE surpasses 60,000 iFuse procedures performed by more than 2,500 surgeons worldwide

SI-BONE, Inc. Announces UnitedHealthcare Adopts Exclusive iFuse Only Coverage for Minimally Invasive SI Joint Fusion

SANTA CLARA, Calif., Aug. 23, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that it will be participating in the following upcoming investor conferences:

SI-BONE to Participate in Upcoming Conferences

SI-BONE Inc (NASDAQ: SIBN) reported Q2 sales of $22.2 million, beating the consensus of $21.96 million, representing a 58% Y/Y increase over the COVID-19 impacted 2020 period. U.S. revenue of $20.2 million increased 53% Y/Y.

SI-BONE Q2 Sales Beat Estimates But Higher Costs Hit Profitability, Maintains FY21 Revenue Outlook

SI-BONE, Inc. (SIBN) CEO Laura Francis on Q2 2021 Results - Earnings Call Transcript

Shares of SI-BONE (NASDAQ:SIBN) were flat in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share increased 4.55% over the past year to ($0.42), which missed the estimate of ($0.39).

SI-BONE: Q2 Earnings Insights

Record Second Quarter 2021 Worldwide Revenue of $22.2 million Record Second Quarter 2021 Worldwide Revenue of $22.2 million

SI-BONE, Inc. Reports Second Quarter 2021 Financial Results and Announces Exclusive Coverage from Anthem

Anthem is America's 2nd largest commercial health insurer and joins more than 35 other health plans to offer coverage exclusively for the triangular iFuse Implant System Anthem is America's 2nd largest commercial health insurer and joins more than 35 other health plans to offer coverage exclusively for the triangular iFuse Implant System

SI-BONE, Inc. Announces Anthem, Inc. Adopts Coverage Guidelines for Sacroiliac Joint Fusion Exclusive to the Triangular iFuse Implant System® for Its More Than 40 Million Members

SANTA CLARA, Calif., July 20, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the second quarter of 2021 after market close on Monday, August 2, 2021. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

SI-BONE To Report Second Quarter 2021 Financial Results on August 2, 2021

New positive coverage policy provides access to iFuse as an important treatment option for patients with chronic sacroiliac joint pain and dysfunction New positive coverage policy provides access to iFuse as an important treatment option for patients with chronic sacroiliac joint pain and dysfunction

SI-BONE, Inc. Announces Centene Establishes Positive Coverage for MIS SI Joint Fusion including the Triangular iFuse Implant System

SI-BONE Inc (NASDAQ: SIBN) has announced the publication of 2-year results from the SALLY study of the iFuse-3D Implant System.  Clinical results at 24 months showed marked and sustained improvements in the sacroiliac (SI) joint pain, patient function, and quality of life.

SI-BONE's Sacroiliac Joint Implant Show Accelerated Fusion, Reduction In Opioid Use

There are now 95 peer-reviewed publications demonstrating the safety, effectiveness, biomechanical or economic benefits of iFuse Technology™ There are now 95 peer-reviewed publications demonstrating the safety, effectiveness, biomechanical or economic benefits of iFuse Technology™

SI-BONE, Inc. Announces Publication of iFuse-3D Implant Clinical Study Results Showing Accelerated Fusion, Immediate and Sustained Clinical Improvements and Reduction in Opioid Use

SANTA CLARA, Calif., July 02, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced the worldwide launch of the SI-BONE SImulator™.

SI-BONE, Inc. Announces the Introduction of the SI-BONE SImulator™ Powered by Medability for iFuse Surgeon Training and Education

Exclusive Coverage Takes Effect June 1, 2021, and Extends for 5 Years Exclusive Coverage Takes Effect June 1, 2021, and Extends for 5 Years

French National Healthcare System Adopts Exclusive Reimbursement Policy for SI-BONE, Inc.'s iFuse-3D Implant System™

SANTA CLARA, Calif., June 08, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that the company will be participating in the upcoming 2021 JMP Securities Life Sciences Conference. Management is scheduled to present on Thursday, June 17 at 2:30 p.m. Eastern Time / 11:30 a.m. Pacific Time.

SI-BONE to Present at the 2021 JMP Securities Life Sciences Conference

SI-BONE, Inc. (SIBN) CEO Laura Francis on Q1 2021 Results - Earnings Call Transcript

Shares of SI-BONE (NASDAQ:SIBN) remained quited after the company reported Q1 results. Quarterly Results Earnings per share were up 21.28% year over year to ($0.37), which beat the estimate of ($0.39).

Recap: SI-BONE Q1 Earnings

SANTA CLARA, Calif., May 03, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the quarter ended March 31, 2021.

SI-BONE, Inc. Reports First Quarter 2021 Financial Results and Reiterates 2021 Financial Guidance

SANTA CLARA, Calif., April 22, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced today that the company will be participating in the upcoming 7th Annual Truist Securities 2021 Life Sciences Summit and the 2021 Bank of America Health Care Conference.

SI-BONE to Present at the 7th Annual Truist 2021 Life Sciences Summit and the 2021 Bank of America Health Care Conference

SANTA CLARA, Calif., April 19, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced the appointment of Anshul Maheshwari as the company's Chief Financial Officer effective April 20, 2021, and the addition of Helen Loh and Laura Francis to its Board of Directors effective April 18, 2021. The appointment of Mr. Maheshwari completes the recently announced senior leadership transition which includes Laura Francis succeeding Jeff Dunn as Chief Executive Officer, and Tony Recupero becoming President, Commercial Operations. Jeff Dunn will remain with the company as Executive Chairman.

SI-BONE Appoints Anshul Maheshwari as Chief Financial Officer and Announces the Addition of Helen Loh and Laura Francis to the Board of Directors

SANTA CLARA, Calif., April 15, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the first quarter of 2021 after market close on Monday, May 3, 2021. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

SI-BONE To Report First Quarter 2021 Financial Results on May 3, 2021

SI-BONE, Inc. (SIBN) CEO Jeff Dunn on Q4 2020 Results - Earnings Call Transcript

Shares of SI-BONE (NASDAQ:SIBN) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 22.22% year over year to ($0.28), which beat the estimate of ($0.30).

Recap: SI-BONE Q4 Earnings

SANTA CLARA, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the quarter and full year ended December 31, 2020.

News for SI-BONE Inc Stock (SIBN)